Our results clearly indicated that not only can blood biomarkers be an effective indicator of cognitive decline in patients with dementia, but the existence of vascular lesions that may affect AD pathology could influence the results of measuring plasma concentration levels of NfL and GFAP. This evidence concerns the gene GFAP and Alzheimer disease.